FDA approves bevacizumab (Avastin) for glioblastoma multiforme
Prescribing information, mechanism of action, approved indications and videos on Avastin (bevacizumab) for glioblastoma multiforme.
Off-label intravitreal use of bevacizumab (Avastin): reports of ocular side effects
Letter from Roche to health care professionals dated December 16, 2008. Related to off- label uses in ophtalmology of bevacizumab (Avastin): Reports of Eye Inflammation, Endophthalmitis, and Toxic Anterior Segment Syndrome (TASS) Following Off-label Intravitreal Use of AVASTIN® (bevacizumab)
Panitumumab (Vectibix) for metastatic colorectal carcinoma. Australian Prescriber review
From Australian Prescriber: Panitumumab Vectibix (Amgen) vials containing 20 mg/mL in 5 mL, 10 mL or 20 mL volume Approved indication: metastatic colorectal carcinoma Australian Medicines Handbook section 14.2.1 Panitumumab is a humanised monoclonal antibody for the treatment of metastatic colorectal carcinomas expressing the epidermal growth factor receptor. It is indicated for patients whose tumours […]